Target intelligence / Profile preview

Immunoglobulin lambda constant 6 (IGLC6)

Target
IGLC6
Molecular classification
Other (Immunoglobulin constant region; not a receptor, enzyme, transporter, or GPCR)
01

Overview

Immunoglobulin lambda constant 6 is the constant region of a lambda-type immunoglobulin (antibody) light chain. It encodes one of several constant region (C) gene segments in the immunoglobulin lambda locus, expressed as part of B-cell receptor or antibody molecules produced by B lymphocytes. The constant region provides structural support and determines the isotype of the antibody light chain but does not contribute to antigen specificity, which is dictated by the variable region. IGLC6 is predicted to have antigen binding activity as part of a complete immunoglobulin. This gene is reported to be a pseudogene or gene/pseudogene and does not independently encode a functional protein in all transcripts. Immunoglobulins are essential for humoral immunity, but this particular constant region is not a therapeutic target, receptor, or enzyme, and no drugs are known to target IGLC6 directly[2][3][7].

Other names
Immunoglobulin lambda constant 6 (Kern+Oz- marker)Ig lambda-6 chain C regionIGLCImmunoglobulin lambda constant 6 (Kern+Oz- marker, gene/pseudogene)Immunoglobulin lambda constant region 6 (Kern+ Oz- marker)Immunoglobulin lambda constant 6 (gene/pseudogene)
02

Biological functions

Immune responseAntigen binding
03

Disease associations

Cancer (Certain immunoglobulin regions can be involved in lymphoid malignancies, though no specific pathogenic role is established for IGLC6)Other (Potential use in disease phenotyping/monitoring, not as a drug target)
04

Biomarkers

Possible use as part of immunoglobulin panels to phenotype B-cell or plasma cell populations (no established or specific clinical biomarker use for IGLC6 individually)

Beyond the preview

Go deeper on Immunoglobulin lambda constant 6 (IGLC6).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Immunoglobulin lambda constant 6 (IGLC6).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call